Beam nasdaq
WebApr 10, 2024 · Beam Therapeutics Price Performance. NASDAQ:BEAM opened at $29.74 on Monday. The firm has a market capitalization of $2.15 billion, a P/E ratio of -7.20 and a beta of 1.63. The business has a 50 ... WebBeam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing...
Beam nasdaq
Did you know?
WebSep 8, 2024 · Find the latest SEC Filings data for Beam Therapeutics Inc. Common Stock (BEAM) at Nasdaq.com.
WebMar 27, 2024 · Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new … Based on analysts offering 12 month price targets for BEAM in the last 3 months. … Nasdaq provides NLS Volume, Previous Close, Today's High & Low, and the 52 … Find the latest on option chains for Beam Therapeutics Inc. Common Stock … Find the latest press releases from Beam Therapeutics Inc. Common Stock … Find the latest historical data for Beam Therapeutics Inc. Common Stock … WebJan 16, 2024 · Beam Therapeutics is a preclinical startup that's developing gene therapies and expects to begin clinical trials in the second half of 2024. Its base-editing technology could be a much more...
WebBeam Therapeutics Inc. Common Stock (BEAM) After-Hours Quotes Nasdaq Search for After Hours Quote After-Hours: BEAM Edit my quotes Beam Therapeutics Inc. Common Stock (BEAM) 0 Add to... WebFind real-time BEAM - Beam Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. ... Beam Therapeutics Inc (NASDAQ:BEAM) 29.76. Delayed Data. As of Apr 12 -0.33 ...
WebMay 10, 2024 · There are some variant perceptions on Beam Therapeutics, with the most bullish analyst valuing it at US$154 and the most bearish at US$62.00 per share. This is a fairly broad spread of estimates,...
WebCAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines … john stallings carrollton gaWebApr 6, 2024 · About Beam Therapeutics Inc. Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which... john stalker productionsWebApr 13, 2024 · Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Rating) have been given a consensus rating of “Moderate Buy” by the eleven brokerages that are currently covering the firm, Marketbeat.com reports.Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month … how to go back in google driveWebNext quarter’s sales forecast for BEAM is $15.61M with a range of $5.00M to $21.30M. The previous quarter’s sales results were $20.04M. BEAM beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.02% of the time in the same period. how to go back in laptop using keyboardWebApr 13, 2024 · Beam Therapeutics (NASDAQ:BEAM – Get Rating) last announced its quarterly earnings data on Tuesday, February 28th. The company reported ($0.54) … john stallings elementary coronaWebBeam Therapeutics Inc (BEAM) Stock Price & News - Google Finance +91.09 +0.13% +2.33 -0.68 Home BEAM • NASDAQ Beam Therapeutics Inc Follow Share $29.74 After … how to go back in inkscapeWebMar 16, 2024 · Beam Therapeutics has a 1 year low of $27.77 and a 1 year high of $73.27. Beam Therapeutics ( NASDAQ:BEAM - Get Rating) last issued its quarterly earnings data on Tuesday, February 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.34) by $0.80. how to go back in iphone